Proprotein convertase subtilisin kexin type 9 (PCSK9) regulates low-density lipoprotein and very low-density lipoprotein receptor expression in several tissues. Here we evaluated whether PCSK9 may modulate the handling of triglycerides in the liver and peripheral tissues.
Methods
Subjects from the PLIC cohort were genotyped for the loss-of-function PCSK9 R46L variant and characterized for clinical and biochemical parameters, total and android fat mass, hepatic steatosis and epicardial fat thickness. Visceral adipose tissue and subcutaneous adipose tissue in PCSK9 KO and wild type mice were quantified by nuclear magnetic resonance imaging.
Results
Carriers of the R46L variant (n = 13) had lower low-density lipoprotein cholesterol levels, higher body mass index and increased percentage of total and android fat masses compared with non-carriers (n = 521). R46L variant associated with a two-fold increase prevalence of hepatic steatosis and higher epicardial fat thickness. These observations were replicated in PCSK9 KO mice, which showed increased visceral adipose tissue (but not subcutaneous adipose tissue) when fed chow or high-fat diet for 20 weeks, compared with wild type mice.
Conclusions
These data suggest that genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.
CariouBOuguerramKZairYet al.PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol2009; 29: 2191–2197.
3.
CohenJCBoerwinkleEMosleyTHJret al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med2006; 354: 1264–1272.
4.
AbifadelMVarretMRabesJPet al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet2003; 34: 154–156.
5.
TavoriHGiunzioniIPredazziIMet al.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res2016; 110: 268–728.
PoirierSMayerGBenjannetSet al.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem2008; 283: 2363–2372.
8.
DemersASamamiSLauzierBet al.PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol2015; 35: 2517–2525.
9.
Le MayCKourimateSLanghiCet al.Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol2009; 29: 684–690.
10.
ZhaoZTuakli-WosornuYLagaceTAet al.Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet2006; 79: 514–523.
11.
PoirierSHamoudaHAVilleneuveLet al.Trafficking dynamics of PCSK9-induced LDLR degradation: Focus on human PCSK9 mutations and C-terminal domain. PLoS One2016; 11: e0157230–e0157230.
12.
LakoskiSGLagaceTACohenJCet al.Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab2009; 94: 2537–2543.
13.
NorataGDGarlaschelliKOngariMet al.Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke2006; 37: 1558–1561.
14.
NorataGDOngariMGarlaschelliKet al.Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med2007; 262: 104–112.
15.
LorenzMWPolakJFKavousiMet al.Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): A meta-analysis of individual participant data. Lancet2012; 379: 2053–2062.
16.
BaragettiAKnoflachMCuccovilloIet al.Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. Nutr Metab Cardiovasc Dis2014; 24: 518–523.
17.
DemetzESchrollAAuerKet al.The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab2014; 20: 787–798.
18.
BaragettiAPalmenJGarlaschelliKet al.Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. J Intern Med2015; 277: 478–487.
19.
BaragettiANorataGDSarcinaCet al.High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med2013; 274: 252–262.
20.
AlbertiKGEckelRHGrundySMet al.Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation2009; 120: 1640–1645.
21.
GrundySMBrewerHBJrCleemanJIet al.Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation2004; 109: 433–438.
22.
BedogniGBellentaniSMiglioliLet al.The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol2006; 6: 33–33.
23.
BaseviVDi MarioSMorcianoCet al.Comment on: American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care2011; 34(Suppl. 1): S11–S61. e53 author reply e4.
24.
ManciaGFagardRNarkiewiczKet al.2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J2013; 34: 2159–2219.
25.
CatapanoALGrahamIDe BackerGet al.2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2016; 37: 2999–3058.
26.
RothneyMPCatapanoALXiaJet al.Abdominal visceral fat measurement using dual-energy X-ray: Association with cardiometabolic risk factors. Obesity (Silver Spring)2013; 21: 1798–1802.
27.
FracanzaniALTiraboschiSPisanoGet al.Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis2016; 246: 208–213.
28.
HamaguchiMKojimaTTakedaNet al.The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med2005; 143: 722–728.
29.
HernaezRLazoMBonekampSet al.Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology2011; 54: 1082–1090.
30.
BaragettiAPisanoGBertelliCet al.Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Nutr Metab Cardiovasc Dis2016; 26: 141–153.
31.
IacobellisGAssaelFRibaudoMCet al.Epicardial fat from echocardiography: A new method for visceral adipose tissue prediction. Obes Res2003; 11: 304–310.
IacobellisG. Epicardial and pericardial fat: Close, but very different. Obesity (Silver Spring)2009; 17. 625; author reply 626-627.
34.
FranssensBTNathoeHMLeinerTet al.Relation between cardiovascular disease risk factors and epicardial adipose tissue density on cardiac computed tomography in patients at high risk of cardiovascular events. Eur J Prev Cardiol2017; 24: 660–670.
TakahashiSSakaiJFujinoTet al.The very low-density lipoprotein (VLDL) receptor: Characterization and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb2004; 11: 200–208.
37.
RoubtsovaAMunkondaMNAwanZet al.Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol2011; 31: 785–791.
38.
DemersASamamiSLauzierBet al.PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol2015; 35: 2517–2525.
39.
VerbeekRBoyerMBoekholdtSMet al.Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy–brief report. Arterioscler Thromb Vasc Biol2017; 37: 43–48.
40.
RayKKLandmesserULeiterLAet al.Inclisiran in patients at high cardiovascular risk with elevated LDL Cholesterol. N Engl J Med2017; 376: 1430–1440.
41.
SchmidtAFSwerdlowDIHolmesMVet al.PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol2017; 5: 97–105.
42.
FerenceBARobinsonJGBrookRDet al.Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med2016; 375: 2144–2153.
43.
NorataGDTibollaGCatapanoAL. PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges. Vascul Pharmacol2014; 62: 103–111.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
